Hypertonic saline solution in the nebulization Review article
Article Sidebar
Published:
Aug 30, 2021
Keywords:
hypertonic saline solution, nebulization, rhinosinusitis, bronchiolitis, cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, asthma
Main Article Content
Abstract
The aim of the study was to present the current place concentrated sea salt solutions (hypertonic salt solutions) used in nebulization in the treatment of respiratory diseases in humans. The focus was on ailments of the lower respiratory tract. Evidence of the efficacy of nebulized hypertonic saline solutions in upper and lower respiratory diseases in children and adults were presented. Particular attention was paid on bronchiolitis, cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease.
Downloads
Download data is not yet available.
Article Details
How to Cite
Emeryk , A., Emeryk-Maksymiuk , J., Janeczek , K., & Jędrzejewski , A. (2021). Hypertonic saline solution in the nebulization. Alergoprofil, 17(3), 34-38. https://doi.org/10.24292/01.AP.173301821
Issue
Section
THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Wingrave W. The nature of discharges and douches. Lancet. 1902: 1373-5.
2. Wikipedia. Woda morska (access: 23.07.2021).
3. Kassel JC, King D, Spurling GK et al. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2010; (3): CD0068213.
4. Emeryk A, Emeryk-Maksymiuk J, Janeczek K et al. Hipertoniczne roztwory soli w terapii chorób dróg oddechowych. Alergoprofil. 2020; 16(3): 10-7.
5. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018; 9(9): CD001506.
6. Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician. 2009; 80(10): 1117-9.
7. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev. 2010; 19: 127-33.
8. Linssen RSN, Ma J, Bem RA et al. Rational use of mucoactive medications to treat pediatric airway disease. Paed Respir Rev. 2020; 36: 8-14.
9. Goralski JL, Wu D, Thelin WR et al. The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018; 51: 1702652.
10. Luan X, Tam JS, Belev G et al. Nebulized hypertonic saline triggers nervous system-mediated active liquid secretion in cystic fibrosis swine trachea. Sci Rep. 2019; 9: 540.
11. Elkins MR, Bye PTP. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011; 104(suppl 1): S2-S5.
12. Safdar A, Shelburne SA, Evans SE et al. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf. 2009; 8(4): 435-49.
13. Rubino I, Oh E, Han S et al. Salt coatings functionalize inert membranes into high-performing filters against infectious respiratory diseases. Sci Rep. 2020; 10: 13875.
14. Munoz AJ, Alasino RV, Garro AG et al. High concentrations of sodium chloride improve microbicidal activity of Ibuprofen against common cystic fibrosis pathogens. Pharmaceuticals. 2018; 11: 47.
15. Hypertonic saline coated face mask for reducing respiratory symptom severity in patients with COVID-19 (access: 2.08.2021).
16. Emeryk A, Pirożyński M. Nebulizacja: czym, jak, dla kogo, kiedy? Polski Konsensus Nebulizacyjny. Medycyna Praktyczna – Pneumonologia. 2013; 1: wyd. spec.: 2-8.
17. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-33.
18. Ari A. Jet, Ultrasonic, and Mesh Nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J Pulm. 2014; 16: 1-7.
19. Werżanowski P, Pirożyński M. Zestawienie inhalatorów dostępnych w Polsce. In: Pirożyński M. ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 43-72.
20. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015; 12(6): 889-900.
21. Pirożyński M, Florkiewicz E, Sosnowski TR. Podstawy nebulizacji – rodzaje inhalatorów. In: Pirożyński M (ed). ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 27-42.
22. Sayed NEE, Abdelrahman MA, Abdelrahim MEA. Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study. Pulm Pharmacol Ther. 2021; 70: 102054.
23. Emeryk A, Pirożyński M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020; 8(4 spec.): 12-8.
24. Nicolson CH, Stirling RG, Borg BM et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012; 106: 661-7.
25. Benjamin J, Tarrant BJ, Le Maitre C et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017; 22: 1084-92.
26. Visser SK, Bye P, Morgan L. Management of bronchiectasis in adults. Med J Aust. 2018; 209(4): 177-83.
27. Pasteur MC, Bilton D, Hill AT; Thoracic Society Bronchiectasis (non-CF) Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65: 1-58.
28. Zhang L, Mendoza-Sassi RA, Wainwright C et al. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008; 4: CD006458.
29. Ralston SL, Lieberthal AS, Meissner HC et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. American Academy of Pediatrics. Pediatrics. 2014; 134(5): e1474-e502.
30. Zhang L, Gunther CB, Franco OS et al. Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: a meta-analysis. Pediatr Pulmonol. 2018; 53(8): 1089-95.
31. Harrison W, Angoulvant F, House S et al. Hypertonic saline in bronchiolitis and type I error: a trial sequential analysis. Pediatrics. 2018; 142(3): e2018114449.
32. House SA, Gadomski AM, Ralston SL. Evaluating the placebo status of nebulized normal saline in patients with acute viral bronchiolitis. A systematic review and meta-analysis. JAMA Pediatr. 2020; 174(3): 250-9.
33. Elliott SA, Lindsay A Gaudet LA et al. Comparative Efficacy of Bronchiolitis Interventions in Acute Care: A Network Meta-analysis. Pediatrics. 2021; 147(5): e2020040816.
34. Buendía JA, Acuña-Cordero R. The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis. BMC Health Serv Res. 2020; 20(1): 1001.
35. GOLD 2021. 2021 Global strategy for prevention, diagnosis and management of COPD (access: 2.08.2021).
36. Bennett WD, Henderson AG, Ceppe A. Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res. 2020; 6: 00269-2020.
37. 2021 GINA Report, Global Strategy for Asthma Management and Prevention (access: 2.08.2021).
38. Bennett WD, Burbank A, Almond M et al. Acute and durable effect of inhaled hypertonic saline on mucociliary clearance in adult asthma. ERJ Open Res. 2021; 7: 00062-2021.
2. Wikipedia. Woda morska (access: 23.07.2021).
3. Kassel JC, King D, Spurling GK et al. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2010; (3): CD0068213.
4. Emeryk A, Emeryk-Maksymiuk J, Janeczek K et al. Hipertoniczne roztwory soli w terapii chorób dróg oddechowych. Alergoprofil. 2020; 16(3): 10-7.
5. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018; 9(9): CD001506.
6. Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician. 2009; 80(10): 1117-9.
7. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev. 2010; 19: 127-33.
8. Linssen RSN, Ma J, Bem RA et al. Rational use of mucoactive medications to treat pediatric airway disease. Paed Respir Rev. 2020; 36: 8-14.
9. Goralski JL, Wu D, Thelin WR et al. The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018; 51: 1702652.
10. Luan X, Tam JS, Belev G et al. Nebulized hypertonic saline triggers nervous system-mediated active liquid secretion in cystic fibrosis swine trachea. Sci Rep. 2019; 9: 540.
11. Elkins MR, Bye PTP. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011; 104(suppl 1): S2-S5.
12. Safdar A, Shelburne SA, Evans SE et al. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf. 2009; 8(4): 435-49.
13. Rubino I, Oh E, Han S et al. Salt coatings functionalize inert membranes into high-performing filters against infectious respiratory diseases. Sci Rep. 2020; 10: 13875.
14. Munoz AJ, Alasino RV, Garro AG et al. High concentrations of sodium chloride improve microbicidal activity of Ibuprofen against common cystic fibrosis pathogens. Pharmaceuticals. 2018; 11: 47.
15. Hypertonic saline coated face mask for reducing respiratory symptom severity in patients with COVID-19 (access: 2.08.2021).
16. Emeryk A, Pirożyński M. Nebulizacja: czym, jak, dla kogo, kiedy? Polski Konsensus Nebulizacyjny. Medycyna Praktyczna – Pneumonologia. 2013; 1: wyd. spec.: 2-8.
17. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-33.
18. Ari A. Jet, Ultrasonic, and Mesh Nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J Pulm. 2014; 16: 1-7.
19. Werżanowski P, Pirożyński M. Zestawienie inhalatorów dostępnych w Polsce. In: Pirożyński M. ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 43-72.
20. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015; 12(6): 889-900.
21. Pirożyński M, Florkiewicz E, Sosnowski TR. Podstawy nebulizacji – rodzaje inhalatorów. In: Pirożyński M (ed). ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 27-42.
22. Sayed NEE, Abdelrahman MA, Abdelrahim MEA. Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study. Pulm Pharmacol Ther. 2021; 70: 102054.
23. Emeryk A, Pirożyński M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020; 8(4 spec.): 12-8.
24. Nicolson CH, Stirling RG, Borg BM et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012; 106: 661-7.
25. Benjamin J, Tarrant BJ, Le Maitre C et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017; 22: 1084-92.
26. Visser SK, Bye P, Morgan L. Management of bronchiectasis in adults. Med J Aust. 2018; 209(4): 177-83.
27. Pasteur MC, Bilton D, Hill AT; Thoracic Society Bronchiectasis (non-CF) Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65: 1-58.
28. Zhang L, Mendoza-Sassi RA, Wainwright C et al. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008; 4: CD006458.
29. Ralston SL, Lieberthal AS, Meissner HC et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. American Academy of Pediatrics. Pediatrics. 2014; 134(5): e1474-e502.
30. Zhang L, Gunther CB, Franco OS et al. Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: a meta-analysis. Pediatr Pulmonol. 2018; 53(8): 1089-95.
31. Harrison W, Angoulvant F, House S et al. Hypertonic saline in bronchiolitis and type I error: a trial sequential analysis. Pediatrics. 2018; 142(3): e2018114449.
32. House SA, Gadomski AM, Ralston SL. Evaluating the placebo status of nebulized normal saline in patients with acute viral bronchiolitis. A systematic review and meta-analysis. JAMA Pediatr. 2020; 174(3): 250-9.
33. Elliott SA, Lindsay A Gaudet LA et al. Comparative Efficacy of Bronchiolitis Interventions in Acute Care: A Network Meta-analysis. Pediatrics. 2021; 147(5): e2020040816.
34. Buendía JA, Acuña-Cordero R. The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis. BMC Health Serv Res. 2020; 20(1): 1001.
35. GOLD 2021. 2021 Global strategy for prevention, diagnosis and management of COPD (access: 2.08.2021).
36. Bennett WD, Henderson AG, Ceppe A. Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res. 2020; 6: 00269-2020.
37. 2021 GINA Report, Global Strategy for Asthma Management and Prevention (access: 2.08.2021).
38. Bennett WD, Burbank A, Almond M et al. Acute and durable effect of inhaled hypertonic saline on mucociliary clearance in adult asthma. ERJ Open Res. 2021; 7: 00062-2021.